key: cord-0924753-tpya48cr authors: Stralin, K.; Wahlstrom, E.; Walther, S.; Heurgren, M.; Bennet-Bark, A. M.; Linden, T.; Holm, J.; Hanberger, H. title: Decline in mortality among hospitalised covid-19 patients in Sweden: a nationwide observational study date: 2020-10-27 journal: nan DOI: 10.1101/2020.10.27.20220061 sha: bd95884e01570875046ab00e74944858c9e612b9 doc_id: 924753 cord_uid: tpya48cr OBJECTIVE It is important to know if mortality among hospitalised covid-19 patients has changed as the pandemic has progressed. The aim of this study was to describe the dynamics of mortality among patients hospitalised for covid-19 in a nationwide study. DESIGN Nationwide observational cohort study of all patients hospitalised in Sweden 1 March to 30 June 2020 with SARS-CoV-2 RNA positivity 14 days before to 5 days after admission, and a discharge code for covid-19. SETTING All hospitals in Sweden. PARTICIPANTS 15 761 hospitalised patients with covid-19, with data compiled by the Swedish National Board of Health and Welfare. MAIN OUTCOME MEASURES Outcome was 60-day all-cause mortality. Patients were stratified according to month of hospital admission. Poisson regression was used to estimate the relative risk of death by month of admission, adjusting for pre-existing conditions, age, sex, care dependency, and severity of illness (Simplified Acute Physiology, version 3), for patients in intensive care units (ICU). RESULTS The overall 60-day mortality was 17.8% (95% confidence interval (CI), 17.2% to 18.4%), and it decreased from 24.7% (95% CI, 23.0% to 26.5%) in March to 13.3% (95% CI, 12.1% to 14.7%) in June. Adjusted relative risk (RR) of death was 0.56 (95% CI, 0.51 to 0.63) for June, using March as reference. Corresponding RR for patients not admitted to ICU and those admitted to ICU were 0.60 (95% CI, 0.53 to 0.67) and 0.61 (95% CI, 0.48 to 0.79), 3 respectively. The proportion of patients admitted to ICU decreased from 19.5% (95% CI, 17.9% to 21.0%) in the March cohort to 11.0% (95% CI, 9.9% to 12.2%) in the June cohort. CONCLUSIONS There was a gradual decline in mortality from March to June 2020 in Swedish hospitalised covid-19 patients, which was independent of pre-existing conditions, age, and sex. Future research is needed to explain the reasons for this decline. The changing covid-19 mortality should be taken into account when management and results of studies from the first pandemic wave are evaluated. 3 respectively. The proportion of patients admitted to ICU decreased from 19.5% (95% CI, 17 .9% to 21.0%) in the March cohort to 11.0% (95% CI, 9.9% to 12.2%) in the June cohort. There was a gradual decline in mortality from March to June 2020 in Swedish hospitalised covid-19 patients, which was independent of pre-existing conditions, age, and sex. Future research is needed to explain the reasons for this decline. The changing covid-19 mortality should be taken into account when management and results of studies from the first pandemic wave are evaluated. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. The Coronavirus Disease 2019 (covid- 19) pandemic has put enormous pressure on the healthcare system in general and on hospitals in particular, despite extensive interventions to reduce spread of the coronavirus SARS-CoV-2. 1 Patients admitted for covid- 19 have been reported to have mortality fractions of ≥20% overall [2] [3] [4] [5] and of >34% among patients admitted to an intensive care unit (ICU). 2, [6] [7] [8] The proportion of patients requiring ICU admission is reported to be 17-32%. 2, [9] [10] [11] Most studies on covid-19 mortality have included patients admitted between February and April 2020, i.e. early in the covid-19 pandemic. 1 Since the outbreak of the pandemic, there has been a gradual and substantial increase in our understanding of covid-19. This may have contributed to the improved survival that has been noted among ICU-treated covid -19 patients. In an ICU study of covid-19 patients in England, Wales and Northern Ireland by Doidge et al., 8 a decline in 28-day mortality was noted from 43.5% before the peak of the first pandemic wave to 34.3% after the peak. A meta-analysis of Armstrong et al. 12 showed lower ICU mortalities in studies published April-May than in those published January-March. However, a large proportion of hospitalised covid-19 patients are never admitted to ICU, and to our knowledge it has not been clarified if mortality has changed among non-ICU treated hospitalised patients. Karagiannidis et al. 5 reported no considerable change in mortality over time in a large German cohort of unselected hospitalised covid-19 patients. The present Swedish study was undertaken to examine whether mortality has changed with time in a nationwide cohort of hospitalised covid-19 patients. The specific aim was to evaluate nationwide 60-day mortality separately for non-ICU treated and ICU treated patients, during the first 4 months of the pandemic, using data compiled by the Swedish National Board of Health and Welfare (NBHW). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020. 10 Nationwide observational cohort study on SARS-CoV-2-positive individuals treated for covid-19 in Swedish hospitals. The study population was derived from cross-linked national population-based registers using the unique personal identity number assigned to each Swedish resident at birth or on immigration to Sweden. 13 From Primary outcome was 60-day mortality, defined as death from any cause within 60 days of index hospital admission. Sixty days was considered to be a reasonable follow-up time since very few patients remain in hospital for longer periods, but patients in ICU often remain hospitalised beyond 30 days. 5 Date of death was obtained from the Swedish Cause of Death Register 15 (held by NBHW). Since the beginning of the covid-19 pandemic, the register has been updated daily with all dates of death, as reported to the Swedish Tax Agency (mandatory reporting by law), resulting in no loss to follow-up. ICU episodes were identified from the Swedish Intensive Care Registry, a national quality register for intensive care in Sweden including 83 of 84 ICUs in the country. 16 Since the outbreak of the pandemic the register has had complete coverage of all ICU treated covid-19 patients in Sweden. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint To account for patient transfer within or between hospitals, resulting in multiple entries in the NPR, duration of hospital stay was defined as number of days between index admission date and last discharge date in cases with sequential admissions. A sequential admission was defined as a readmission occurring within 1 day of the previous one, starting with the index admission. Duration of hospital stay in days was compared using the outcome discharge status (alive/deceased) rather than 60-day mortality, to avoid truncating one group at 60 days by default. Comorbidities were defined using discharge diagnoses for the last five years and/or prescribed drugs dispensed during the year preceding index admission. A 30-day wash-out window prior to index admission date was applied. Codes defining each comorbidity are provided in table E1. In addition, Charlson Comorbidity Index (CCI) was calculated as described in table E2. Information on discharge diagnoses were identified through the NPR, which contains information on all reported cases of inpatient care and/or visits to a physician at a specialised outpatient clinic in Sweden. The validity of the register is generally high with positive predictive values of 85% to 95% for most diagnoses in validation studies. 17 Data on drugs dispensed were obtained from the Swedish Prescribed Drug Register (held by NBHW), which contains all prescribed and pharmacy-dispensed medicines in the community classified according to the Anatomic Therapeutic Chemical Classification System (ATC). It has almost complete coverage (data missing <1%). 18 Information on care dependency (nursing home resident or homecare) prior to admission was obtained from the Care and Social Services for the Elderly and for Persons with Impairments Register (held by NBHW). Date and country of birth were obtained from the NPR. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint patient had several ICU admissions, treatment information was retrieved for all episodes of ICU care for covid-19. Baseline patient characteristics were tabulated by month of admission, ICU treatment and survival outcome. Confidence intervals (CI) were calculated for proportions using the Wilson Score interval and expressed as percentages. Crude survival curves with 95% Hall-Wellner confidence bands were estimated using the Kaplan-Meier estimator, plotted by month of admission with all-cause mortality as event. Follow-up was truncated at 60 days after index admission. The log-rank test was used to test for differences in survival between groups, with a two-sided alpha of 0.05. Furthermore, percentage mortalities were plotted by month of admission, overall, by age groups (<60, 60-69, 70-79, ≥80), sex, and healthcare region. Incident number of covid-19 patients admitted to hospital per day was plotted by index admission date for the whole patient cohort as well as separately for ICU, using the first occurring ICU admission date for a patient. The number of covid-19 patients residing in hospital care per day was also calculated, again showing one curve for the overall cohort and one for the ICU treated cohort separately. Lines were smoothed using a seven-day rolling average, based on three days prior-three days after admission. Relative risk (RR) with 95% CI was estimated in multivariable analysis for the outcome 60day mortality with month of hospitalisation as exposure of interest, using modified Poisson regression models. 19 Estimates of RR were obtained from three models: Model 1 adjusted for age (continuous, both a linear and quadratic term), sex (male/female), CCI (categorical, 0, 1-2, 3-4, 5+), care dependency (nursing home, homecare, neither), country of birth (Sweden/other), and healthcare region (North, Uppsala-Örebro, Stockholm-Gotland, Southeast, West, and South). Model 2 additionally included an interaction term between month of admission and healthcare region. Model 3 estimated age as a categorical variable (<60, 60-69, 70-79, ≥80) for increased interpretability, and included an interaction term between month of admission and age group. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint 8 Model 1 was also stratified between ICU admission or not during the hospital episode. In cases of ICU care, the SAPS3 score (continuous) for the first ICU episode was added, creating In all regression models, missing data were handled by complete case analysis. Data were complete on all variables except for country of birth and CCI (5% missing) and SAPS3 (<1% missing). Sensitivity analyses were performed comparing adjusted RR when imputing missing country of birth to 'Sweden' or 'Outside Sweden', and when imputing missing CCI to extreme values '0' or '5+'. All data management and statistical analyses were performed using SAS Software SAS Enterprise guide v7.15, SAS Institute Inc., Cary, NC. Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research. Ethical approval for the study was obtained from the Swedish Ethics Review Authority, Uppsala (Dnr 2020-04278). The study conforms to the Reporting of Observational Studies in Epidemiology (STROBE) statement. 20 Altogether, 15 761 patients admitted for covid-19 in Swedish hospitals were studied, median age 64 years (interquartile range, 51 to 78 years), 57.5% men and 42.5% women. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Kaplan-Meier analysis confirmed mortality differences according to month of admission, with a log-rank p-value <0.001 for both non-ICU and ICU treated patients (fig 4) . The survival curves showed a higher initial mortality rate for the March cohort than for the other months of admission, most clearly so for those admitted to ICU. In multivariable regression analyses, the decrease in mortality remained throughout the study period with an adjusted relative risk (RR) of 0.56 (95% CI, 0.51 to 0.63) in June, using March as reference. Adjusted mortality, with March as reference, decreased in patients not treated on ICU with RR 0.60 (95% CI, 0.53 to 0.67), and in patients treated on ICU with RR 0.61 (95% . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. Tables E4-E5 show the relative risks from model 3 and 4, i.e. per month of admission separately by healthcare region and age respectively. There was a significant interaction both for age group and healthcare region (Joint test p<0.001). In the healthcare regions, the overall mortality in March ranged from 15.0% to 28.0%. The decline in mortality was most pronounced in the healthcare region with the highest initial mortality, i.e. Stockholm-Gotland, which also had the highest number of covid-19 cases/population (table E4 and E6, fig E6) . In June, the overall mortality ranged from 10.3% to 15.3% in 5 healthcare regions, although it was 19.1% in one healthcare region (North). As shown in fig 6, the proportion of patients admitted to ICU decreased from 19.5% (95% CI, 17.9% to 21.0%) in the March cohort to 11.0% (95% CI, 9.9% to 12.2%) in the June cohort, and the overall proportion receiving invasive mechanical ventilation decreased from 16.8% (95% CI, 15.4% to 18.4%) to 6.4% (95% CI, 5.6% to 7.4%). Table 3 The present nationwide study on patients hospitalised for covid-19 in Sweden showed a distinct gradual decline in 60-day mortality between March and June both for non-ICU treated and ICU treated patients. The results were stable after adjustment for pre-existing conditions, age, sex, level of care dependency, country of birth, healthcare region, and SAPS3 (ICU treated patients). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint The mortalities of 17.9% among hospitalised covid-19 patients overall and 25.5% among ICU treated covid-19 patients were low compared to reported mortalities from other countries, i.e. ≥ 20% 2-5 and > 34%, 2,6-8 respectively. Reasons for differences in outcome are difficult to analyse since studies use different outcome definitions, provide different patient characteristics, and often include patients that are still treated in hospital. Importantly, the time period of inclusion is probably crucial for the overall mortality and for differences between studies, since the mortality has clearly been changing over time. In the present study, the overall 60-day mortality declined from 24.7% in March to 13.3% in June, it declined from 36.1% to 20.1% among ICU treated patients, and from 21.9% to 12.5% among non-ICU patients requiring oxygen therapy after June 16, when the RECOVERY RCT showed survival benefits from corticosteroids. 26 Prior to that, corticosteroids were predominantly used on the ICU, and their use increased over the study period (table 3) . However, the infrequent use of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint 13 interpreted with caution. The impact of an intervention during a high-mortality period does not necessarily apply to the same intervention during a period with significantly lower mortality. This is important when planning for allocation of healthcare resources to meet the next phases of the pandemic. The present study has a number of strengths. First, it was a nationwide study including all hospitals in Sweden, minimising risk of selection bias. Second, it was based on national registers with standardised reporting on a national level, minimising bias of ascertainment. patients. Fourth, the use of 60-day mortality provided a robust outcome measure with a follow-up long enough to enable hospital discharge of most patients. The study also has limitations. First, clinical data regarding organ function were not available for non-ICU treated patients. Thus, it was not possible to determine degree of respiratory failure within the whole cohort. Second, data on do-not-resuscitate orders were not available and thus, it is not known if criteria for admission to ICU changed with time. However, SAPS3 scores on ICU admission were constant throughout the study period, indicating that the criteria for ICU admission had probably not changed considerably. Third, we did not have access to data on drug therapy on wards during hospital stay, and thus we could not appropriately assess the impact of different drug therapy for outcome. Fourth, the NPR lacks information from primary care, hence the CCI may be underestimated. However, replacing CCI with the individual comorbidities measured from both the NPR and the Prescribed Drug Register (thus catching primary care) in the models did not attenuate RR estimates further (not shown). In conclusion, there was a distinct gradual decline in mortality for both non-ICU treated and ICU treated hospitalised covid-19 patients. Future studies are needed to address and explain this decline. The changing covid-19 mortality should be considered when the management and results of studies from the first pandemic wave are evaluated. . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint All authors conceived and designed the study. KS, EW, SW, ABB, MH, JH and HH acquired data. EW and JH performed analyses and interpreted these together with KS, SW and HH. EW and JH verified the underlying data in the article. EW and JH drafted and finalised all tables and figures. KS and EW contributed equally. KS drafted the first version of the manuscript. All authors had full access to data in the study and accept responsibility for submission for publication. All authors revised the manuscript critically for important intellectual content and approved the final version for submission. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: No competing interests. The results of this work will be disseminated to the public through press releases and media commentary. We are unable to directly provide the results of the research to study participants as this study analyzed deidentified data. The data underlying this article cannot be shared publicly due to regulations under the Swedish law. According to the Swedish Ethical Review Act, the General Data Protection Regulation, the Public Access to Information and Secrecy Act, data can only be made available, after legal review, for researchers who meet the criteria for access to this type of confidential data. Requests regarding the data may be made to the senior author. This study was funded by Sweden's National Board of Health and Welfare. The authors thank Anastasia Nyman for valuable discussion and support. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint CCI = Charlson Comorbidity Index. . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study Trends in intensive care for patients with COVID-19 in England, Wales and Northern Ireland Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) Decreasing mortality rates in ICU during the COVID-19 pandemic The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research SmiNet-2: Description of an internetbased surveillance system for communicable diseases in Sweden The Swedish cause of death register No association with cardiac death after sepsis: A nationwide observational cohort study External review and validation of the Swedish national inpatient register The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months A modified poisson regression approach to prospective studies with binary data The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted October 27, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted October 27, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted October 27, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted October 27, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.27.20220061 doi: medRxiv preprint